Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.
A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
The company said revenues from its clinical lab services rose 9 percent because of high demand for certain molecular diagnostic services.
The company has installed Illumina's HiSeq X sequencing platform and expects to sequence 20,000 genomes by the end of next year.
The three-year trial used immunoassays and PCR testing, and found 335 Babesia microti positive samples among 89,153 blood donations.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.